Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
Prucalopride medicine in the form of Orally Disintegrating Strips are most convenient dosage form for geriatric patients
Medical footprint expansion with deeper medical grade skin contact material science expertise
Since its launch, the medical devices park in Sultanpur has received overwhelming response with more than 50 companies lining up to set up their manufacturing or research and development units
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
While continuing to offer its current breadth of genomic services, Biogazelle will become CellCarta's Center of Excellence for the development of complex genomic biomarker assays
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
Intox is a GLP certified pre-clinical contract research organization with its test facilities in Pune
It accelerates the company’s vision for transforming healthcare and advancing patient care worldwide – from the hospital to the home
Subscribe To Our Newsletter & Stay Updated
